Position in MGTX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$108,475
-$94,476 QoQ
Shares Held
12,526
-49.2% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MGTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in MGTX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $108,475 | 12,526 | Shares | Sole | 2026-05-08 | |
| 2025-09-30 | $202,951 | 24,660 | Shares | Sole | 2025-11-07 | |
| 2025-03-31 | $103,306 | 15,237 | Shares | Sole | 2025-05-08 | |
| 2024-06-30 | $83,248 | 19,774 | Shares | Sole | 2024-08-15 | |
| 2023-03-31 | $135,696 | 26,247 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $350,802 | 53,804 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $486,333 | 57,828 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $234,927 | 31,034 | Shares | Sole | 2022-08-09 | |
| No filing history on record for this holder in this stock. | ||||||